华海药业(600521) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was CNY 2,368,563,881.42, a decrease of 5.21% compared to CNY 2,498,671,124.15 in the same period last year[3] - Net profit attributable to shareholders increased by 9.81% to CNY 297,404,077.75 from CNY 270,842,789.22 year-on-year[3] - Basic and diluted earnings per share rose by 10.53% to CNY 0.21 from CNY 0.19 in the same period last year[3] - The company reported a net profit of ¥366,117,225.22 for Q1 2025, down from the previous year's profit[16] - The net profit for Q1 2025 was CNY 296,039,678.32, an increase of 8.4% compared to CNY 273,944,434.55 in Q1 2024[17] - The operating profit for Q1 2025 was CNY 376,768,523.14, slightly up from CNY 374,627,295.80 in Q1 2024[17] Cash Flow - The net cash flow from operating activities decreased significantly by 77.13%, down to CNY 195,107,658.86 from CNY 853,246,043.03 in the previous year[3] - The cash flow from operating activities generated a net amount of CNY 195,107,658.86, a significant decrease of 77% compared to CNY 853,246,043.03 in Q1 2024[19] - Total cash inflow from operating activities was CNY 1,575,964,162.08, down from CNY 2,175,596,868.47, reflecting a decrease of about 27.5%[29] - The total increase in cash and cash equivalents was CNY 301,086,829.70, down from CNY 1,368,577,829.51, indicating a decrease of approximately 78.0%[29] Assets and Liabilities - Total assets at the end of the reporting period increased by 6.10% to CNY 21,497,389,091.79 from CNY 20,261,354,969.92 at the end of the previous year[4] - Total liabilities increased to ¥11,594,754,851.80 as of March 31, 2025, compared to ¥11,241,320,819.01 at the end of 2024, an increase of 3.1%[13] - The company's total current assets amounted to CNY 9.94 billion as of March 31, 2025, compared to CNY 9.31 billion at the end of 2024, reflecting a growth of 6.7%[22] - Total liabilities decreased slightly to CNY 7.71 billion as of March 31, 2025, from CNY 7.82 billion on December 31, 2024, a reduction of about 1.4%[23] Shareholder Information - The company reported a total of 62,676 common shareholders at the end of the reporting period[7] - The top shareholder, Chen Baohua, holds 24.46% of the shares, totaling 368,877,935 shares[8] - Shareholders' equity attributable to the parent company increased by 9.91% to CNY 9,779,249,594.43 from CNY 8,897,779,286.94[4] Research and Development - Research and development expenses increased to ¥238,907,980.88 in Q1 2025, compared to ¥213,856,487.20 in Q1 2024, marking an increase of 11.7%[16] - Research and development expenses rose to CNY 110.41 million in Q1 2025, up 34.4% from CNY 82.15 million in Q1 2024, indicating a focus on innovation[24] Future Outlook - The company did not report any significant new product developments or market expansion strategies during this quarter[9] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[24] - The company plans to implement new accounting standards starting in 2025, which may impact future financial reporting[30]